The London-based medtech startup Mendelian is on the mission to improve the lives of patients by diagnosing rare diseases faster. Recently, the startup has received an endowment of €570k from Innovate UK. The financing will be employed in developing solutions enabling physicians to determine rare diseases.
Piers Ricketts, Chief Executive at the Eastern Academic Health Science Network said, “We are delighted to support Mendelian as part of our work into rare diseases. With over 3 million rare disease patients in the UK, innovative technologies using data analytics and machine learning like this are increasingly vital in ensuring that these conditions are diagnosed earlier to provide more targeted and personalised treatment for patients.”
Mendelian – analyses phenotypes as well as genotypes
Mendelian’s high-tech digital technology offers customised solutions for patients, physicians, healthcare providers and pharmaceutical companies. The medtech startup has built the most comprehensive knowledge base for rare diseases by analysing phenotypes, genotypes and syndrome of patients along with clinical investigations.
Technology-driven fast diagnosis with accuracy
The automated screening system curated by Mendelian, efficiently identifies patients with rare diseases through augmented intelligence and data analysis. After evaluating a patient’s symptoms, the general physician is alerted and the patient is guided towards the precise treatment.
50,000 users in over 150 countries
Mendelian owns a users base of 50,000 spread over 150 countries. The startup maintains strong collaborations with renowned institutions including Imperial College London, Harvard Medical School, Rady Children’s Hospital and Genetic Alliance.
Dr. Peter Fish, Head of Clinical Partnerships at Mendelian expressed, “It’s clear that this ‘diagnostic odyssey’ is not only causing patients distress and emotional turmoil but is also extremely frustrating for clinicians, as well as costly for healthcare systems and ultimately tax-payers.”
Dr. Fish further added, “To help solve this pressing issue we’re delighted to be providing a solution within the NHS, for not only rare disease patients but also those with hard to diagnose conditions. Crucially, Mendelian’s technology is being implemented at the general practice stage, right at the beginning of the patient journey with the aim of identifying these conditions as early on as possible.”
Stock photos from metamorworks/Shutterstock
Stay tuned to Silicon Canals for more updates in the tech startup world.